R61
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 59
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- INTERFERON_ALPHA_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- ALLOGRAFT_REJECTION+0.280
- ANGIOGENESIS+0.270
- OXIDATIVE_PHOSPHORYLATION+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- IL6_JAK_STAT3_SIGNALING+0.220
- UV_RESPONSE_UP+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.350
- UV_RESPONSE_DN-0.350
- ANDROGEN_RESPONSE-0.310
- WNT_BETA_CATENIN_SIGNALING-0.280
- FATTY_ACID_METABOLISM-0.220
- MTORC1_SIGNALING-0.220
- HEDGEHOG_SIGNALING-0.210
- PANCREAS_BETA_CELLS-0.210
- SPERMATOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-A4CD-01A-21R-A24Z-07 | — | — | 0.741 |
| 2 | SRR12475141 | — | — | 0.736 |
| 3 | c4779698-5c81-4eed-80ac-80fdd47f658b | — | — | 0.722 |
| 4 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.718 |
| 5 | MNG1091 | — | — | 0.711 |
| 6 | SRR4195685 | — | — | 0.709 |
| 7 | TCGA-CV-A6JZ-01A-11R-A31N-07 | — | — | 0.709 |
| 8 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.707 |
| 9 | MNG1140 | — | — | 0.706 |
| 10 | SRR12475171 | — | — | 0.684 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |